Rewriting the Fate of AML: Stopping Cancer Before It Starts

What if we could prevent acute myeloid leukaemia (AML) before malignant stem cells fully transform into cancer cells?

Researchers at the University of Oslo - Faculty of Medicine have uncovered a powerful biological switch — a signaling pathway involving succinate and its receptor SUCNR1 — that determines whether bone marrow stem cells remain healthy or turn cancerous.

🔍 The Breakthrough

Using spectral flow cytometry, RNA sequencing, and advanced stem cell analysis — combined with AML mouse models — the team demonstrated that adjusting levels of succinate, SUCNR1, and S100A9 can directly influence leukaemia development.

📊 Critical Clinical Insight

Low SUCNR1 levels in patients are linked to poorer survival outcomes, positioning SUCNR1 as both:

• A potential prognostic biomarker

• A promising therapeutic target

⚡ A Paradigm Shift

Succinate has long been viewed as a driver of cancer progression. This study reveals a protective role when it acts through SUCNR1 — challenging conventional cancer biology assumptions.

🎯 Why This Matters

Instead of targeting fully developed cancer cells, this research focuses on the earliest transformation step — the stem cell “decision point.”

This could enable:

✔ Personalized treatment strategies based on SUCNR1 levels

✔ Earlier intervention before aggressive AML develops

✔ New biotech and pharmaceutical innovation pathways

🚀 The next step: Translating the succinate/SUCNR1 pathway into real-world therapeutic strategies.

If validated in clinical settings, this approach could redefine how we detect, stratify, and treat AML — shifting from reaction to prevention.